No Data
Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept
Editas Medicine, Inc. (NASDAQ:EDIT) Is Largely Controlled by Institutional Shareholders Who Own 64% of the Company
Wells Fargo Sticks to Their Buy Rating for Editas Medicine (EDIT)
Toronto Stocks Advance Friday
National Bank on DRI Healthcare's Casgevy Stream Acquisition
Leerink Partners Maintains Editas Medicine(EDIT.US) With Hold Rating, Maintains Target Price $8
No Data
No Data
TranceHead : thought you weren't going to be on today my friend. Take care and look after yourself. i look forward to your posts on your return. hoping you get a bill of clean health.